Larimar Therapeutics (LRMR) Other Accumulated Expenses (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Other Accumulated Expenses for 14 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses rose 99.4% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2026 stood at $1.3 million (up 99.4% YoY), and the FY2025 full-year result was $777000.0, up 38.5% from the prior year.
• Other Accumulated Expenses grew to $1.3 million in Q2 2026 per LRMR's latest filing, from $777000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $1.3 million in Q2 2026 and bottomed at $427000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $706588.2 across 5 years, with a median of $662000.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses soared 416.56% in 2022, then plunged 38.65% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $441000.0 in 2022, then declined by 3.17% to $427000.0 in 2023, then soared by 31.38% to $561000.0 in 2024, then soared by 38.5% to $777000.0 in 2025, then jumped by 69.88% to $1.3 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.3 million, $777000.0, and $881000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.